Listed

Sunshine Biopharma Inc.: Form 10-K for the period ended Dec 31, 2015

Filed with the SEC on Mar 25, 2016 and accepted by EDGAR at Mar 25, 2016, 15:57 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2015-01-01 to 2015-12-31$1.7kus-gaap:SalesRevenueGoodsNet
Research and development12 months2015-01-01 to 2015-12-31$8.7kus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2015-01-01 to 2015-12-31−$780.3kus-gaap:OperatingIncomeLoss
Interest expense12 months2015-01-01 to 2015-12-31$307.2kus-gaap:InterestExpense
Net income12 months2015-01-01 to 2015-12-31−$1.7mus-gaap:NetIncomeLoss
Basic EPS12 months2015-01-01 to 2015-12-31−$0.01us-gaap:EarningsPerShareBasic
Operating cash flow12 months2015-01-01 to 2015-12-31−$867.6kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2015-01-01 to 2015-12-31$4.8kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2015-12-31$50.8kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-12-31$53.9kus-gaap:AssetsCurrent
Total assetsAt period end2015-12-31$673.3kus-gaap:Assets
Current liabilitiesAt period end2015-12-31$1.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2015-12-31$1.3mus-gaap:Liabilities
Shareholders' equityAt period end2015-12-31−$597.0kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001354488-16-006700. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.